Dr. Christina Cone Honored With The Mary Pazdur Award for Excellence in Advanced Practice in Oncology by APSHO
APSHO presented the third annual Mary Pazdur Award for Excellence in Advanced Practice in Oncology to Christina Cone of the Duke Cancer Institute at the JADPRO Live Virtual conference...
Final Efficacy Results From the ExteNET Trial: Neratinib in Pretreated Patients With HR-Positive, HER2-Positive Early Breast Cancer
An analysis from the phase III ExteNET trial found significant improvements with the administration of neratinib in patients with HR-positive, HER2-positive early breast cancer...
Are Delays in Breast Cancer Treatment as Harmful as Commonly Thought?
Delays in the treatment of breast cancer matter, but not as much “as we and our patients typically assume,” Richard J. Bleicher informed participants at the Lynn Sage Breast Cancer Symposium...
Neoadjuvant Dual Checkpoint Blockade in Certain Patients With Localized Bladder Cancer
Neoadjuvant combination therapy with tremelimumab and durvalumab showed early signs of activity in patients ineligible to receive cisplatin-based chemotherapy...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Princess Dina Mired on Mobilizing for Greater Equity in Health Care Despite the Challenges of COVID-19
Rujuta Saksena: The New Face of Medical Visits
Kimberly T. Lee on Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer
Rawad Elias on Reasons to ‘Geriatricize’ Your Oncology Practice: Research Updates From ASCO20
Govind Persad: Developing Policies to Address Patient Racial Bias and Race-Based Provider Requests
Sponsored Content
Sponsored By Bayer
Treatment and Sequencing in Metastatic Castration-Resistant Prostate Cancer
Sponsored by QED Therapeutics
Recent Advances in the Treatment of FGFR-Altered Advanced Cholangiocarcinoma
Addition of Bevacizumab to Paclitaxel in Relapsed Ovarian Sex Cord–Stromal Tumors
In the phase II ALIENOR trial reported in JAMA Oncology, Isabelle Ray-Coquard, MD, and colleagues found that the addition of bevacizumab to paclitaxel did not improve the 6-month progression-free rate among women with relapsed ovarian sex cord–stromal tumors. Study Details The study, performed in...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Addition of Oxaliplatin to Preoperative Capecitabine-Based Chemoradiation and Adjuvant Capecitabine in Locally Advanced Rectal Cancer
As reported in the Journal of Clinical Oncology by Schmoll et al, the phase III PETACC 6 trial has shown no benefit of the addition of preoperative and adjuvant oxaliplatin to preoperative capecitabine-based chemoradiation and adjuvant capecitabine in patients undergoing total mesorectal excision...
Camrelizumab Plus Apatinib in Previously Treated Patients With Advanced Cervical Cancer
In the Chinese phase II CLAP study reported in the Journal of Clinical Oncology, Lan et al found that the combination of the anti–PD-1 antibody camrelizumab and the VEGFR inhibitor apatinib produced high response rates in previously treated women with advanced cervical cancer. Study Details The...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Research Into 'Cold' Tumors Heating Up in Pancreatic Cancer
Immunotherapy has changed the treatment paradigm for cancer, inducing durable responses in a subset of patients with previously refractory disease. However, current approaches are successful in only approximately 20% of cancers (so-called hot tumors). For the nearly 80% of cancers that are “cold”...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
